Nuclear Medicine and Biology

Perspective Therapeutics Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals

Retrieved on: 
Monday, November 27, 2023
University of Alabama, Molecular imaging, VMT, Hospital, SSTR2, Neoplasm, University college, Survival, University of Iowa, NGAL, Veterinary medicine, Biology, Lipocalin-2, RPDC, Nuclear Medicine and Biology, Becquerel, Nuclear medicine, University, Quality control, Medicine, Doctor of Philosophy, Therapy, TU Dresden, Korea Military Academy, Knowledge, Biomarker, Toxicity, CATX, Radiopharmaceutical, PB, European Journal, Journal, Institute of technology, Glomus tumor, Medical imaging

SEATTLE, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced the publication of four preclinical studies in support of the Company’s discovery pipeline. The studies were published in the European Journal of Nuclear Medicine and Molecular Imaging, Journal of Nuclear Medicine, and Pharmaceuticals.

Key Points: 
  • SEATTLE, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced the publication of four preclinical studies in support of the Company’s discovery pipeline.
  • The studies were published in the European Journal of Nuclear Medicine and Molecular Imaging, Journal of Nuclear Medicine, and Pharmaceuticals.
  • “The results from these preclinical studies are compelling and continue to support our ongoing clinical efforts to advance our novel lead-based targeted alpha-particle therapies.
  • Author Affiliations: University of Alabama at Birmingham, Alabama, USA; Perspective Therapeutics, Coralville, Iowa, USA; The University of Iowa, Iowa City, Iowa, USA.

Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights

Retrieved on: 
Tuesday, November 14, 2023
Lung, Lutetium (177Lu) oxodotreotide, Seed, EANM, Patient, Clinical study report, Research, Radiation therapy, Marketing, Stony Brook University, UPMC Hillman Cancer Center, Medullary thyroid cancer, Growth, Congress, University, Fortis Healthcare, Pelvic exenteration, Radiation, PRRT, Toxicity, IND, GEP-NET, MTC, Melanoma, Perspective, CATX, Communication, NET, Society, ASTRO, Therapy, NETS, Wilfrid Sellars, Brain, Biology, Nuclear Medicine and Biology, Glomus tumor, NYSE, PET/CT, SPECT/CT, Clinical trial, MC1R, Prostate cancer, NIH, Survival, UPMC, GEP, Rare-earth element, Medical imaging, Pharmaceutical industry, Medical device, Cryptocurrency, Nuclear medicine, Brachytherapy

Two additional patients were enrolled in the third quarter for a total of 9 GEP-NET patients and 2 medullary thyroid cancer (MTC) patients.

Key Points: 
  • Two additional patients were enrolled in the third quarter for a total of 9 GEP-NET patients and 2 medullary thyroid cancer (MTC) patients.
  • Third quarter 2023 revenue was the highest since the second quarter of 2022, with a return to growth over the third quarter of 2022.
  • Total operating expenses for the quarter ended September 30, 2023 were $11.3 million, compared to $4.6 million for the same period in 2022, an increase of 144%.
  • Cash and cash equivalents as of September 30, 2023 was $18.0 million as compared to $43.9 million on December 31, 2022.

Global Technetium Market (2021 to 2026) - Featuring American Elements, Bayer and Covidien Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, October 25, 2021
Health, Chemicals, Plastics, Manufacturing, Other Health, Radiology, Other Manufacturing, Biotechnology, Neutron, Technetium, COVID-19, Nuclear medicine, Acute coronary syndrome, Particle, Bone, Geography, Industry, Nuclear fission product, Radionuclide, Organization, PET, Particle accelerator, Myocardial perfusion imaging, Biology, LVAD, Government, Metal powder, Coronary heart disease, susceptibility to, 8, Brain, Investment, Fault, Deep vein thrombosis, Growth, Inflammation, Nuclear Medicine and Biology, SPECT, Thrombus, Employment, Pulmonary embolism, Medical imaging

This report provides deep insights into the current and future state of the technetium market across various regions.

Key Points: 
  • This report provides deep insights into the current and future state of the technetium market across various regions.
  • The report examines the market drivers and restraints, along with the impact of Covid-19 on the market's growth, in detail.
  • According to the publisher, the global technetium market is expected to witness growth at a considerable rate during the forecast period.
  • Boasting high development, North America has been the largest market for global technetium due to the demand for advanced medical facilities here.